SEC Filing Summary: PharmAthene, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PharmAthene, Inc. on August 3, 2007. The filing relates to the consummation of a Merger transaction. The report was filed concurrently with a separate Form 8-K due to the number of items exceeding the single-form limit. The filing indicates that upon the consummation of the Merger, Former PharmAthene acquired control of the combined corporation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Item 2.03 notes the creation of a direct financial obligation through Convertible Notes issued in connection with the Merger, but specific terms and amounts are incorporated by reference from a Definitive Proxy Statement and are not detailed in this text.
Material Changes
- Change in Control: A change in control of the registrant occurred upon the consummation of the Merger, with Former PharmAthene acquiring control of the combined entity.
- Debt Obligation: The company created a direct financial obligation via the issuance of Convertible Notes as part of the Merger transaction.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. It directs readers to the Definitive Proxy Statement (pages 57 and 80) for detailed descriptions of the Merger and the Convertible Notes. No unusual items or contingencies are explicitly described in this text.
Investor Verification Checklist
- Verify the specific terms, interest rates, and conversion features of the Convertible Notes referenced in the Definitive Proxy Statement.
- Confirm the exact ownership structure and control details of the combined corporation post-merger.
- Review the full Definitive Proxy Statement for comprehensive details on the Merger transaction not included in this 8-K.